Quality and Value

SITC 2019 Quality Summit Consensus Report

Published on Jan. 16, 2020, in the Journal for ImmunoTherapy of Cancer (JITC), Defining Current Gaps in Quality Measures for Cancer Immunotherapy: Consensus Report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit serves as the society’s initial effort towards the goal of identifying, developing, and implementing quality measures dedicated to improving and standardizing immunotherapeutic-based cancer care. Generated by a SITC multi-stakeholder expert panel, this manuscript presents potential immunotherapy quality measure concepts within four relevant National Quality Strategy domains that could be developed and broadly adopted by the field, including:

  • Patient safety
  • Person and family-centered care
  • Care coordination and communication
  • Appropriate treatment selection

This consensus statement is initial work lead by the society that will seek to further define and standardize quality delivery of cancer immunotherapy to realize the treatment’s optimal application and benefit for patients. Click here to read the entire manuscript.

SITC Cancer Immunotherapy Guidelines

Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.18CIG-logo-rgb.jpg

In response to the ever-growing demand for expert advice on the optimal use of immunotherapy treatments, SITC Cancer Immunotherapy Guidelines Subcommittees have developed consensus statements for variety of disease states, including genitourinary malignancies (renal and prostate carcinoma), hematologic malignancies (multiple myeloma, lymphoma and acute leukemia), melanoma and more.

Click here for a complete listing of the guidelines and links to view.

Commission on Cancer

SITC is the first and only organization dedicated to cancer immunotherapy to be accepted as a formal member of the Commission on Cancer (CoC), a program of the American College of Surgeons.

Pai_Sara.jpgThe CoC is the nation’s leading accreditation body for cancer care and has established a strong partnership approach to defining and measuring quality as it relates to managing patients with cancer. Today, more than 80 percent of Americans with cancer will seek treatment at a CoC accredited facility.

SITC represents leaders of the field of cancer immunotherapy, to help establish and implement immunotherapy at CoC-accredited institutions and develop mechanisms for collecting data and educating healthcare providers on the optimal way to deliver immunotherapy. SITC member Sara Pai, MD, PhD, Associate Surgeon and Professor at Harvard Medical School and the Massachusetts General Hospital, serves as SITC's official liaison to the Commission..

Foundation for the Accreditation of Cellular Therapy (FACT) CAR-T Cell Task Force

SITC has been a key collaborator in the development of the Foundation for the Accreditation of Cellular Therapy (FACT) Standards for Immune Effector Cell Administration.Marcela Maus, MD, PhD of Harvard Medical School serves as SITC’s official liaison to the FACT CAR-T Cell Task Force.

SITC provided formal comments to the FACT draft of the 1st edition FACT Standards for Immune Effector Cell Administration. These standards are intended to promote quality in the administration of immune effector cells and will be incorporated into a voluntary FACT accreditation in this field.

Click here to download "Standards for Immune Effector Cell Administration".